CF
PHAT icon

Corebridge Financial’s Phathom Pharmaceuticals PHAT Stock Holding History

Corebridge Financial’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,532
Closed -$122K – 2021
2025
Q1 		$122K Buy
19,532
+24
+0.1% +$146 ﹤0.01% 2338
2024
Q4 		$158K Buy
19,508
+1,263
+7% +$15.6K ﹤0.01% 2308
2024
Q3 		$330K Sell
18,245
-113
-0.6% -$1.58K ﹤0.01% 1945
2024
Q2 		$189K Buy
+18,358
New +$189K ﹤0.01% 2230

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Corebridge Financial's PHAT Position: Q2 2025 in Review

Corebridge Financial sold out of Phathom Pharmaceuticals (PHAT) in Q2 2025, closing a stake of 19,532 shares — an estimated $122K sold.

Corebridge Financial first reported a position in PHAT in Q2 2024 and held it in 4 quarters. The position peaked at $330K in Q3 2024. 117 funds tracked by Wall St. Rank hold PHAT as of Q2 2025.

  • Corebridge Financial reported no remaining Phathom Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 19,532 Phathom Pharmaceuticals shares in Q2 2025, an estimated $122K.
  • Corebridge Financial first reported a position in Phathom Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Phathom Pharmaceuticals position peaked at $330K in Q3 2024.
  • 117 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.